Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: The HEP-COVID randomized clinical trial
JAMA — Spyropoulos AC, Goldin M, Giannis D, et al. | October 11, 2021
The HEP-COVID multicenter randomized clinical trial was conducted to determine if therapeutic-dose low-molecular-weight heparin (LMWH), vs institutional standard prophylactic or intermediate-dose heparins, for thromboprophylaxis results in reduction in the incidence of major thromboembolism and death in high-risk hospitalized patients with COVID-19.
A randomized clinical trial including 253 adults.
With therapeutic-dose, the incidence of major thromboembolism or death was 28.7% relative to 41.9% with prophylactic/intermediate-dose heparins; a significant difference—driven by reduction in thromboembolism—that was not observed in critically ill patients.
The groups did not show any significant difference in major bleeding.
Overall findings revealed reduced occurrence of the composite outcome of major thromboembolism and death in high-risk inpatients with COVID-19 in correlation with thromboprophylaxis with therapeutic-dose low-molecular-weight heparin.
Read the full article on JAMA